Orally active, selective phosphodiesterase type 5 (PDE5) inhibitor. Prepn: U. Niewhner et al., WO 9924433; eidem, US 6362178 (1999, 2002 both to Bayer AG). Effect on cGMP in human corpus cavernosum muscle cells: N. N. Kim et al., Life Sci. 69, 2249 (2001). Pharmacology: E. Bischoff et al., J. Urol. 165, 1316 (2001). Clinical trial in impotence: H. Porst et al., Int. J. Impot. Res. 13, 192 (2001); in erectile dysfunction: C. Stief et al., Int. J. Clin. Pract. 58, 230 (2004); F. Giuliano et al., BJU Int. 95, 110 (2005). Review of clinical experience in erectile dysfunction: S. Markou et al., Int. J. Impot. Res. 16, 470-478 (2004); M. Kendirci et al., Expert Opin. Pharmacother. 5, 923-932 (2004).
In treatment of male erectile dysfunction.
Phosphodiesterase Inhibitor; Impotence Therapy